KRRO (Korro Bio, Inc.) Expected net earnings per share growth this year

Official company branding of korrobio.com (KRRO)

The Korro Bio, Inc. (KRRO) ecosystem is limited to clinical trial stages under FDA supervision. The current YoY EPS growth rate helps assess fundamental value, with the metric standing at 60.20. Revenue is projected to be generated through the implementation of the OPERA platform for treating rare pathologies. Simultaneously, the company is implementing energy-saving systems and emission filtration in its laboratories to comply with ESG standards.

Net earnings per share growth this year: Korro Bio, Inc (KRRO) for 02/21/2024 - 11/13/2026

Analytical breakdowns and data insights for company korrobio.com (KRRO)

- share price and consensus valuation forecast:
Price Chart Korro Bio|KRRO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Korro Bio|KRRO - Total Company Value
- shareholders' equity book value data:
Net Asset Value per Share Korro Bio|KRRO - Company Net Assets|Market Value to Book Value korrobio.com|KRRO - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Coefficient Korro Bio, Inc.|KRRO - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Korro Bio|KRRO - Company Aggregate Debts|Debt to Book Value Korro Bio|KRRO - Company Long-Term Liabilities|Short-Term Debt Volume Korro Bio|Quick Ratio korrobio.com
- company profitability and valuation multiples indicators:
KRRO - Company Net Income|Expected Net Income Korro Bio, Inc.|KRRO - Price to Earnings Ratio|Future Price to Earnings Multiple Korro Bio|KRRO - Price/Earnings to Growth Ratio|Company Value to EBITDA Korro Bio|KRRO - Operating profit EBITDA|Earnings per share for the last 12 months Korro Bio|KRRO - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months korrobio.com|KRRO - Earnings growth in current year|Earnings growth forecast for next year Korro Bio, Inc.
Fundamental valuation:KRRO, Korro Bio, Inc
Mass-produced product of Korro Bio, Inc

For Korro Bio, Inc. (KRRO), which operates in experimental RNA editing without current revenue, earnings per share dynamics reflect the capital burn rate and cost management efficiency. This metric measures the annual percentage change in net income, allowing the year-over-year EPS growth rates to assess the fundamental sustainability of the business amid multi-billion dollar investments prior to commercialization.

Key competitors

TEM (Tempus Labs) - Earnings per share growth in current year|QGEN (Qiagen Group) - Earnings growth in current year|Isis Pharmaceuticals (IONS) - Expected net earnings per share growth this year|Earnings per share growth in current year Repligen Corporation (RGEN)|RNA - Earnings per share growth rate in current year|CRISPR Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year WGS|Ultragenyx Pharma - Earnings growth in current year|Expected net earnings per share growth this year Beam Tx BEAM|Sarepta Therapeutics, Inc. (SRPT) - Earnings per share growth in current year|Earnings per share growth this year TWST|TXG (10x Genomics) - Earnings growth in current year|Net earnings per share growth this year Intellia Therapeutics Inc (NTLA)|Net earnings per share growth this year STOK (Stoke)|Expected net earnings per share growth this year BioLife|Earnings per share growth in current year Wave Life Sciences WVE|Earnings growth in current year mazetx.com MAZE|SION - Earnings per share growth in current year|Earnings per share increase in current year PRME (Prime Medicine Inc)|Taysha (TSHA) - Earnings per share growth in current year|uniQure Pharma - Earnings per share increase in current year|Earnings per share growth in current year MeiraGTx Holdings plc|Earnings per share growth rate in current year regenxbio.com RGNX|Earnings growth in current year SLDB|Ocugen Inc - Earnings per share growth this year|Earnings per share growth in current year Pacific Biosciences of California PACB|BNTC: Earnings per share growth this year|Design Therapeutics - Earnings growth in current year|RCKT - Earnings growth in current year|4D Molecular Therapeutics, Inc. (FDMT) - Earnings per share growth in current year|Lexeo Therapeutics, Inc. (LXEO) - Earnings growth in current year|Earnings per share growth in current year Editas|Earnings per share growth rate in current year Silence Therapeutics Corp SLN|Earnings per share growth in current year ProQR Therapeutics N.V. (PRQR)|CDXS (codexis.com) - Earnings per share increase in current year|Earnings per share growth in current year Sangamo Therapeutics, Inc. SGMO|Earnings per share increase in current year NAUT|MGX - Earnings per share growth in current year|Earnings per share growth rate in current year precisionbiosciences.com|GBIO (generationbio.com) - Net earnings per share growth this year|boundlessbio.com - Earnings per share increase in current year|XCUR (Exicure Inc.) - Earnings growth in current year|Earnings per share growth in current year IMNN|Earnings growth in current year PHIO|Expected net earnings per share growth this year mustangbio.com|Earnings per share growth in current year TransCode Therapeutics, Inc. RNAZ|Bionano Genomics Inc. (BNGO) - Earnings per share growth rate in current year|APDN: Net earnings per share growth this year|Earnings per share increase in current year BLUE (bluebird bio Inc.)|IPA: Earnings growth in current year|OMGA - Expected net earnings per share growth this year|Earnings per share growth in current year Singular Genomics Systems|Earnings per share growth this year RGLS (regulusrx.com)|Earnings growth in current year SYRS|Net earnings per share growth this year Telesis Bio Inc. TBIO|TRACON - Net earnings per share growth this year|Expected net earnings per share growth this year Unity Biotechnology, Inc (UBX)